No Data
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6.88
Morgan Stanley analyst Maxwell Skor maintains $Atea Pharmaceuticals(AVIR.US)$ with a hold rating, and maintains the target price at $6.88.According to TipRanks data, the analyst has a success rate
Atea Pharmaceuticals: Hold Rating Amidst Clinical Trial Setbacks and Future HepC Focus
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Atea Pharmaceuticals Resumed Trading